Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96


Chiral Resolution and Serendipitous Fluorination Reaction for the Selective Dopamine D3 Receptor Antagonist BAK2-66.

Kumar V, Banala AK, Garcia EG, Cao J, Keck TM, Bonifazi A, Deschamps JR, Newman AH.

ACS Med Chem Lett. 2014 Mar 24;5(6):647-51. doi: 10.1021/ml500006v. eCollection 2014 Jun 12.


Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.

Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH.

J Med Chem. 2005 Feb 10;48(3):839-48.


N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity.

Banala AK, Levy BA, Khatri SS, Furman CA, Roof RA, Mishra Y, Griffin SA, Sibley DR, Luedtke RR, Newman AH.

J Med Chem. 2011 May 26;54(10):3581-94. doi: 10.1021/jm200288r. Epub 2011 May 2.


Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse.

Mason CW, Hassan HE, Kim KP, Cao J, Eddington ND, Newman AH, Voulalas PJ.

J Pharmacol Exp Ther. 2010 Jun;333(3):854-64. doi: 10.1124/jpet.109.165084. Epub 2010 Mar 12.


Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907).

van Vliet LA, Rodenhuis N, Dijkstra D, Wikström H, Pugsley TA, Serpa KA, Meltzer LT, Heffner TG, Wise LD, Lajiness ME, Huff RM, Svensson K, Sundell S, Lundmark M.

J Med Chem. 2000 Jul 27;43(15):2871-82.


Selectivity and activation of dopamine D3R from molecular dynamics.

Feng Z, Hou T, Li Y.

J Mol Model. 2012 Dec;18(12):5051-63. doi: 10.1007/s00894-012-1509-x. Epub 2012 Jul 3.


Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor.

Brown DA, Mishra M, Zhang S, Biswas S, Parrington I, Antonio T, Reith ME, Dutta AK.

Bioorg Med Chem. 2009 Jun 1;17(11):3923-33. doi: 10.1016/j.bmc.2009.04.031. Epub 2009 Apr 19.


Using click chemistry toward novel 1,2,3-triazole-linked dopamine D3 receptor ligands.

Keck TM, Banala AK, Slack RD, Burzynski C, Bonifazi A, Okunola-Bakare OM, Moore M, Deschamps JR, Rais R, Slusher BS, Newman AH.

Bioorg Med Chem. 2015 Jul 15;23(14):4000-12. doi: 10.1016/j.bmc.2015.01.017. Epub 2015 Jan 17.


Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist.

Chien EY, Liu W, Zhao Q, Katritch V, Han GW, Hanson MA, Shi L, Newman AH, Javitch JA, Cherezov V, Stevens RC.

Science. 2010 Nov 19;330(6007):1091-5. doi: 10.1126/science.1197410.


Microbial/enzymatic synthesis of chiral drug intermediates.

Patel RN.

Adv Appl Microbiol. 2000;47:33-78. Review.


Dopamine D3 receptor binding of (18)F-fallypride: Evaluation using in vitro and in vivo PET imaging studies.

Mukherjee J, Constantinescu CC, Hoang AT, Jerjian T, Majji D, Pan ML.

Synapse. 2015 Dec;69(12):577-91. doi: 10.1002/syn.21867. Epub 2015 Oct 15.


High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice.

Boateng CA, Bakare OM, Zhan J, Banala AK, Burzynski C, Pommier E, Keck TM, Donthamsetti P, Javitch JA, Rais R, Slusher BS, Xi ZX, Newman AH.

J Med Chem. 2015 Aug 13;58(15):6195-213. doi: 10.1021/acs.jmedchem.5b00776. Epub 2015 Jul 23.


A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors.

Michino M, Donthamsetti P, Beuming T, Banala A, Duan L, Roux T, Han Y, Trinquet E, Newman AH, Javitch JA, Shi L.

Mol Pharmacol. 2013 Dec;84(6):854-64. doi: 10.1124/mol.113.087833. Epub 2013 Sep 23.


Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists.

Furman CA, Roof RA, Moritz AE, Miller BN, Doyle TB, Free RB, Banala AK, Paul NM, Kumar V, Sibley CD, Newman AH, Sibley DR.

Eur Neuropsychopharmacol. 2015 Sep;25(9):1448-61. doi: 10.1016/j.euroneuro.2014.11.013. Epub 2014 Nov 29.


Exploration of the impact of stereochemistry on the identification of the novel translocator protein PET imaging agent [(18)F]GE-180.

Chau WF, Black AM, Clarke A, Durrant C, Gausemel I, Khan I, Mantzilas D, Oulie I, Rogstad A, Trigg W, Jones PA.

Nucl Med Biol. 2015 Sep;42(9):711-9. doi: 10.1016/j.nucmedbio.2015.05.004. Epub 2015 May 27.


Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype.

Robarge MJ, Husbands SM, Kieltyka A, Brodbeck R, Thurkauf A, Newman AH.

J Med Chem. 2001 Sep 13;44(19):3175-86. Erratum in: J Med Chem 2002 Aug 29;45(18):4056.


An improved method for the synthesis of protected glycosyl fluorides from thioglycosides using N,N-diethylaminosulfur trifluoride (DAST).

Suzuki K, Ito Y, Kanie O.

Carbohydr Res. 2012 Oct 1;359:81-91. doi: 10.1016/j.carres.2012.07.003. Epub 2012 Jul 14.


(R)-(-)- and (S)-(+)-Synadenol: synthesis, absolute configuration, and enantioselectivity of antiviral effect.

Qiu YL, Hempel A, Camerman N, Camerman A, Geiser F, Ptak RG, Breitenbach JM, Kira T, Li L, Gullen E, Cheng YC, Drach JC, Zemlicka J.

J Med Chem. 1998 Dec 17;41(26):5257-64.


Supplemental Content

Support Center